following an abbreviated submission
insulin detemir (Levemir®) is accepted for restricted use within NHS Scotland.
Indication under review: for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
SMC restriction: in patients unable to achieve good glycaemic control with established insulins.
Insulin detemir has previously been accepted for restricted use by SMC in adults, adolescents and children from 2 years of age. Insulin detemir is included in the British National Formulary for Children (November 2015).
Download detailed advice110KB (PDF)
Medicine details
- Medicine name:
- insulin detemir (Levemir)
- SMC ID:
- 1126/16
- Indication:
For treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
- Pharmaceutical company
- Novo Nordisk Ltd
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 07 March 2016
Novo Nordisk has advised that insulin detemir (Levemir®) FlexPen® 100units/mL solution for injection in pre-filled pens and insulin detemir (Levemir®) Penfill® 100units/mL solution for injection in cartridges are being discontinued from the end of December 2026. SMC advice for these products will be removed from the SMC website shortly thereafter.